StoxBiocon vs Ipca Laboratories: share price & financials comparison
NSE: BIOCON vs IPCALAB · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Biocon vs Ipca Laboratories at a glance
Biocon (BIOCON) has a market capitalisation of ₹59,326 Cr, against ₹47,797 Cr for Ipca Laboratories (IPCALAB). Over the past year Ipca Laboratories has returned +45.5%, compared with -4.3% for Biocon. On valuation, Ipca Laboratories trades at a lower P/E of 34.1 versus 131.2. Ipca Laboratories earns a higher return on equity (16.2% vs 1.3%). Biocon comes out ahead on valuation. Ipca Laboratories comes out ahead on size, profitability, growth, financial health, momentum and technicals. Across the scored metrics below, Biocon leads on 4 and Ipca Laboratories on 14. On StoxGud's 10-point checklist, Biocon scores 2/10 and Ipca Laboratories scores 8/10.
| Metric | Biocon | Ipca Laboratories |
|---|---|---|
| Size | ||
| Market cap | ₹59,326 Cr | ₹47,797 Cr |
| Revenue (latest FY) | ₹16,927 Cr | ₹9,646 Cr |
| Net profit (latest FY) | ₹386 Cr | ₹1,141 Cr |
| Valuation | ||
| P/E | 131.2 | 34.1 |
| P/B | 1.70 | 5.51 |
| Dividend yield | 0.15% | 0.11% |
| Profitability | ||
| Return on equity | 1.3% | 16.2% |
| Net profit margin | 2.6% | 13.4% |
| Operating margin | 20.3% | 22.5% |
| Growth | ||
| Revenue growth (YoY) | +2.2% | +13.8% |
| Net profit growth (YoY) | -51.1% | +32.8% |
| Revenue CAGR (multi-year) | +19.0% | +12.2% |
| Financial health | ||
| Debt to equity | 0.43 | 0.07 |
| Momentum | ||
| 1-month return | +3.7% | -1.8% |
| 1-year return | -4.3% | +45.5% |
| 3-year CAGR | +17.0% | +21.3% |
| 5-year CAGR | +0.1% | +11.4% |
| 10-year CAGR | +9.8% | +21.4% |
| Distance from 52W high | -17.4% | -6.2% |
| Technicals | ||
| RSI (14) | 76 | 38 |
| Price vs 200-day avg | -6.7% | +11.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Biocon | Ipca Laboratories |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✗ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✗ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 2/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Biocon or Ipca Laboratories?
Biocon has a market cap of ₹59,326 Cr and Ipca Laboratories has a market cap of ₹47,797 Cr as of 13 Nov 2026.
Which has a lower P/E, Biocon or Ipca Laboratories?
Ipca Laboratories has the lower P/E: Biocon trades at 131.2 and Ipca Laboratories at 34.1.
Which gave better returns in the last year, Biocon or Ipca Laboratories?
Ipca Laboratories did better: Biocon returned -4.3% and Ipca Laboratories returned +45.5% over one year.
What is the difference between Biocon and Ipca Laboratories?
Both are NSE-listed companies in Healthcare. Biocon is about 1.2 times the size of Ipca Laboratories by market cap. In the latest financial year Biocon reported revenue of ₹16,927 Cr and Ipca Laboratories ₹9,646 Cr. Operating margin is 20.3% for Biocon and 22.5% for Ipca Laboratories. Debt to equity is 0.43 for Biocon and 0.07 for Ipca Laboratories.
Which is better, Biocon or Ipca Laboratories?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Biocon leads on 4 and Ipca Laboratories on 14. Biocon is ahead on valuation. Ipca Laboratories is ahead on size, profitability, growth, financial health, momentum and technicals. On StoxGud's rules-based checklist Biocon scores 2/10 and Ipca Laboratories scores 8/10. This is information, not advice: consult a SEBI-registered adviser before investing.